您当前的位置: 首页 > 资源详情

MedicalXpress,8月6日,A test that detects COVID-19 variants in your spit

编译者:YUTING发布时间:Aug 16, 2021点击量:524 来源栏目:最新研究

With the Delta variant wreaking havoc on unvaccinated populations and COVID-19 cases spiking around the world, the pandemic is far from over. Despite the impressively fast development of SARS-CoV-2 diagnostic tests over the last year and a half, the vast majority of patient samples must still be sent to a lab for processing, which slows down the pace of COVID-19 case tracking. If a sample is to be tested for a specific variant of the virus, it must be genetically sequenced, which takes even more time and resources.

Now, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Massachusetts Institute of Technology (MIT), and several Boston-area hospitals have created an inexpensive, CRISPR-based diagnostic test that allows users to test themselves for SARS-CoV-2 and multiple variants of the virus using a sample of their saliva at home, with no extra instrumentation needed.

The diagnostic device, called Minimally Instrumented SHERLOCK (miSHERLOCK), is easy to use and provides results that can be read and verified by an accompanying smartphone app within one hour. It successfully distinguished between three different variants of SARS-CoV-2 in experiments, and can be rapidly reconfigured to detect additional variants like Delta. The device can be assembled using a 3D printer and commonly available components for about $15, and re-using the hardware brings the cost of individual assays down to $6 each.

"miSHERLOCK eliminates the need to transport patient samples to a centralized testing location and greatly simplifies the sample preparation steps, giving patients and doctors a faster, more accurate picture of individual and community health, which is critical during an evolving pandemic," said co-first author Helena de Puig, Ph.D., a Postdoctoral Fellow at the Wyss Institute and MIT.

The diagnostic device is described in a paper published today in Science Advances.

From supply chain to SHERLOCK

As an Instructor in Pediatrics at Boston Children's Hospital with a specialization in infectious diseases, co-first author Rose Lee, M.D. has been working on the front lines of the COVID-19 pandemic for over a year. Her experiences in the clinic provided inspiration for the project that would ultimately become miSHERLOCK.

"Simple things that used to be ubiquitous in the hospital, like nasopharyngeal swabs, were suddenly hard to get, so routine sample processing procedures were disrupted, which is a big problem in a pandemic setting," said Lee, who is also a Visiting Fellow at the Wyss Institute. "Our team's motivation for this project was to eliminate these bottlenecks and provide accurate diagnostics for COVID-19 with less reliance on global supply chains, and could also accurately detect the variants that were starting to emerge."

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 10月11日_SARS-CoV-2变体对mRNA疫苗诱导的免疫反应的影响
  2. 2 10月11日_SARS-CoV-2变体对mRNA疫苗诱导的免疫反应的影响
  3. 3 Medicalxpress,10月11日,Vaccines prevent severe COVID, even from Delta: study
  4. 4 10月11日_疫苗接种可预防严重COVID-19
  5. 5 PR Newswire,10月11日,INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
  6. 6 10月11日_INOVIO扩展其COVID-19疫苗INO-4800的3期研究
  7. 7 ACCESSWIRE,10月11日,NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
  8. 8 10月11日_NV-CoV-2具有广谱的抗冠状病毒活性
  9. 9 CIDRAP,10月11日,Merck applies for approval of first COVID-19 antiviral pill
  10. 10 10月11日_默沙东向FDA申请首款COVID-19抗病毒药丸的EUA

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190